Dr. Arash Rezazadeh Kalebasty, MD

Dr. Rezazadeh Kalebasty practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Rezazadeh Kalebasty's NPI, 1205974755, was assigned on February 4, 2007. Dr. Rezazadeh Kalebasty graduated from Shahid Beheshti University of Medical Sciences in 1998. Dr. Rezazadeh Kalebasty's California license number on file is C167307.

Dr. Rezazadeh Kalebasty's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Rezazadeh Kalebasty's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Rezazadeh Kalebasty is also affiliated with Hoag Hospital Newport Beach. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rezazadeh Kalebasty practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rezazadeh Kalebasty's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rezazadeh Kalebasty is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Rezazadeh Kalebasty's licenses on file in 3 states: California, Indiana and Kentucky.

Dmand AI lists prostate cancer among the conditions Dr. Rezazadeh Kalebasty treats.

CMS data shows 2,148 Medicare services from Dr. Rezazadeh Kalebasty across 4 procedure codes in 2024, for 247 Medicare patients. Medicare paid $152,720 for them.

CMS counts 247 Medicare patients who saw Dr. Rezazadeh Kalebasty in 2024. The largest group is 65 to 74, with 108 patients. 75% of them have cancer, and 75% have high blood pressure. 37% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rezazadeh Kalebasty's median patient age at 71, with 9% women.

In 2024, Dr. Rezazadeh Kalebasty wrote 1,431 Medicare Part D claims for 150 patients. 49% of them were for generic drugs. CMS names the drug for 1,371 of them, across 19 drugs with 11 or more claims each, at $6,914,083 in total drug cost. In 2023, CMS named 1,078 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Rezazadeh Kalebasty for performance year 2024, reported through an alternative payment model (APM). Dr. Rezazadeh Kalebasty accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rezazadeh Kalebasty as offering telehealth.

Dmand AI links 37 papers to Dr. Rezazadeh Kalebasty, published from 2020 to 2025. 2024 was the busiest year, with 8. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Kidney Neoplasms and Carcinoma, Transitional Cell. Dr. Rezazadeh Kalebasty has published most often in BJU Int. Dr. Rezazadeh Kalebasty's most frequent co-authors are David J. Benjamin, MD, Nataliya Mar, MD and Omid Yazdanpanah, MD.

Dmand AI links Dr. Rezazadeh Kalebasty to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Carcinoma, Transitional Cell and Prostatic Neoplasms. Bristol-Myers Squibb sponsors the most, 2. Open Payments lists research payments to Dr. Rezazadeh Kalebasty that name 3 trials.

CMS Open Payments shows 900 general payments to Dr. Rezazadeh Kalebasty from 30 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 67% of the total. Janssen Pharmaceuticals, Inc paid the most, $166,706. It also lists 13 research payments totaling $54,992 from 2016 to 2025, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Rezazadeh Kalebasty, most recently CMS Stage 1 EHR in 2013.

Dr. Rezazadeh Kalebasty graduated from Shahid Beheshti University of Medical Sciences in 1998.

Dr. Rezazadeh Kalebasty is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.